Literature DB >> 22441390

Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.

Apichaya Puangpetch1, Robert Anderson, Yan Y Huang, Rasana W Sermswan, Wanpen Chaicumpa, Stitaya Sirisinha, Surasakdi Wongratanacheewin.   

Abstract

Melioidosis is a severe disease caused by the Gram-negative bacterium Burkholderia pseudomallei. Previously we showed that pretreatment of mice with CpG oligodeoxynucleotide (CpG ODN) 2 to 10 days prior to B. pseudomallei challenge conferred as high as 90% protection, but this window of protection was rather short. In the present study, we therefore aimed to prolong this protective window and to gain further insight into the mechanisms underlying the protection induced by CpG ODN against B. pseudomallei infection. It was found that the CpG ODN incorporated with cationic liposomes (DOTAP) but not zwitterionic liposomes (DOPC) provided complete protection against bacterial challenge. Although marked elevation of gamma interferon (IFN-γ) was found in the infected animals 2 days postinfection, it was significantly lowered by the DOTAP-plus-CpG ODN pretreatment. When appropriately activated, the phagocytic index and oxidative burst responses of neutrophils appeared not to be elevated. However, macrophages from stimulated mice showed higher levels of nitric oxide production and exhibited higher levels of antimicrobial activities, judging from lower numbers of viable intracellular bacteria. Taken together, our results demonstrate that DOTAP can enhance the protective window period of CpG ODN to at least 30 days and provide 100% protection against B. pseudomallei infection. The protective effect of DOTAP plus CpG ODN could provide an alternative approach to preventing this lethal infection, for which no vaccine is yet available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441390      PMCID: PMC3346326          DOI: 10.1128/CVI.05545-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  47 in total

1.  Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response.

Authors:  H Weighardt; C Feterowski; M Veit; M Rump; H Wagner; B Holzmann
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

2.  CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.

Authors:  David A Rozak; Herbert C Gelhaus; Mark Smith; Mojgan Zadeh; Louis Huzella; David Waag; Jeffrey J Adamovicz
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-05

Review 3.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice.

Authors:  Katrin Breitbach; Sonja Klocke; Thomas Tschernig; Nico van Rooijen; Ulrich Baumann; Ivo Steinmetz
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

5.  Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing.

Authors:  P Utaisincharoen; N Tangthawornchaikul; W Kespichayawattana; P Chaisuriya; S Sirisinha
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

6.  A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei.

Authors:  Anna Easton; Ashraful Haque; Karen Chu; Roman Lukaszewski; Gregory J Bancroft
Journal:  J Infect Dis       Date:  2006-11-21       Impact factor: 5.226

7.  Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents.

Authors:  Chris Druar; Fei Yu; Jodie L Barnes; Richard T Okinaka; Narisara Chantratita; Steve Beg; Chad W Stratilo; Andrew J Olive; Glenn Soltes; Michelle L Russell; Direk Limmathurotsakul; Robert E Norton; Sally X Ni; William D Picking; Paul J Jackson; Don I H Stewart; Vadim Tsvetnitsky; Wendy L Picking; John W Cherwonogrodzky; Natkunam Ketheesan; Sharon J Peacock; Erik J Wiersma
Journal:  FEMS Immunol Med Microbiol       Date:  2007-11-11

8.  Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.

Authors:  David N Harland; Karen Chu; Ashraful Haque; Michelle Nelson; Nicola J Walker; Mitali Sarkar-Tyson; Timothy P Atkins; Benjamin Moore; Katherine A Brown; Gregory Bancroft; Richard W Titball; Helen S Atkins
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

9.  Polysaccharides and virulence of Burkholderia pseudomallei.

Authors:  M Sarkar-Tyson; J E Thwaite; S V Harding; S J Smither; P C F Oyston; T P Atkins; R W Titball
Journal:  J Med Microbiol       Date:  2007-08       Impact factor: 2.472

10.  A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins.

Authors:  Ashraful Haque; Karen Chu; Anna Easton; Mark P Stevens; Edouard E Galyov; Tim Atkins; Rick Titball; Gregory J Bancroft
Journal:  J Infect Dis       Date:  2006-09-25       Impact factor: 5.226

View more
  11 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

Review 3.  Emerging role of biologics for the treatment of melioidosis and glanders.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Alfredo G Torres
Journal:  Expert Opin Biol Ther       Date:  2019-10-15       Impact factor: 4.388

Review 4.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

Review 5.  Treatment and prophylaxis of melioidosis.

Authors:  David Dance
Journal:  Int J Antimicrob Agents       Date:  2014-02-03       Impact factor: 5.283

Review 6.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

7.  Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy.

Authors:  Mona Yazdani; Zahra Gholizadeh; Amin Reza Nikpoor; Nema Mohamadian Roshan; Mahmoud Reza Jaafari; Ali Badiee
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

8.  Monitoring Therapeutic Treatments against Burkholderia Infections Using Imaging Techniques.

Authors:  Tiffany M Mott; R Katie Johnston; Sudhamathi Vijayakumar; D Mark Estes; Massoud Motamedi; Elena Sbrana; Janice J Endsley; Alfredo G Torres
Journal:  Pathogens       Date:  2013-06-01

9.  Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy.

Authors:  Mona Yazdani; Mahdi Hatamipour; Behrang Alani; Hossein Nikzad; Nema Mohamadian Roshan; Javad Verdi; Mahmoud Reza Jaafari; Mahdi Noureddini; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

10.  Vaccines for the Prevention of Melioidosis and Glanders.

Authors:  Monica M Johnson; Kristy M Ainslie
Journal:  Curr Trop Med Rep       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.